The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

被引：0
作者：
Al-Sawaf, Othman [1 ,2 ,3 ,4 ,5 ]
Hallek, Michael [1 ,2 ,3 ]
Fischer, Kirsten [1 ,2 ,3 ]
机构：
[1] Univ Cologne, Fac Med, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[3] Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, German CLL Study Grp, Aachen, Germany
[4] Francis Crick Inst, London, England
[5] UCL, UCL Canc Inst, London, England
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
Chemoimmunotherapy; chronic lymphocytic leukemia (CLL); fixed-duration therapy; minimal residual disease (MRD); targeted agents; OPEN-LABEL; FLOW-CYTOMETRY; FOLLOW-UP; INDEPENDENT PREDICTOR; CELL TRANSPLANTATION; CLL; RITUXIMAB; VENETOCLAX; FLUDARABINE; CHEMOIMMUNOTHERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods have been established to measure and quantify MRD during and after therapy. The improved sensitivity of MRD measurements has made it possible to develop limited-duration therapies, first with chemotherapy and chemoimmunotherapy and now also with combined targeted therapy. Moreover, concepts to integrate MRD information beyond prognostication-to guide duration of treatment and determine sensitivity-are at present being explored in prospective trials. In this review, we summarize currently available methods of MRD detection, provide recent MRD data and outcomes from clinical trials in CLL, and discuss open questions and future approaches for MRD within and outside clinical trials.
引用
收藏
页码：97 / 103
页数：7
相关论文
共 69 条
  • [1] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
    Ahn, Inhye E.
    Farooqui, Mohammed Z. H.
    Tian, Xin
    Valdez, Janet
    Sun, Clare
    Soto, Susan
    Lotter, Jennifer
    Housel, Stephanie
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Maric, Irina
    Calvo, Katherine R.
    Nierman, Pia
    Hughes, Thomas E.
    Saba, Nakhle S.
    Marti, Gerald E.
    Pittaluga, Stefania
    Herman, Sarah E. M.
    Niemann, Carsten U.
    Pedersen, Lone B.
    Geisler, Christian H.
    Childs, Richard
    Aue, Georg
    Wiestner, Adrian
    [J]. BLOOD, 2018, 131 (21) : 2357 - 2366
  • [2] Al-Sawaf O., 2021, HEMATOL ONCOL, V39, P205
  • [3] Al-Sawaf O, 2021, Hematol Oncol, V39
  • [4] Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
    Al-Sawaf, Othman
    Zhang, Can
    Lu, Tong
    Liao, Michael Z.
    Panchal, Anesh
    Robrecht, Sandra
    Ching, Travers
    Tandon, Maneesh
    Fink, Anna-Maria
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Chyla, Brenda
    Miles, Dale
    Wendtner, Clemens-Martin
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (36) : 4049 - +
  • [5] Al-Sawaf O, 2020, LANCET ONCOL, V21, P1188, DOI 10.1016/S1470-2045(20)30443-5
  • [6] Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
    Boettcher, S.
    Stilgenbauer, S.
    Busch, R.
    Brueggemann, M.
    Raff, T.
    Pott, C.
    Fischer, K.
    Fingerle-Rowson, G.
    Doehner, H.
    Hallek, M.
    Kneba, M.
    Ritgen, M.
    [J]. LEUKEMIA, 2009, 23 (11) : 2007 - 2017
  • [7] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
    Boettcher, Sebastian
    Ritgen, Matthias
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Busch, Raymonde M.
    Fingerle-Rowson, Guenter
    Fink, Anna Maria
    Buehler, Andreas
    Zenz, Thorsten
    Wenger, Michael Karl
    Mendila, Myriam
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Doehner, Hartmut
    Hallek, Michael J.
    Kneba, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 980 - 988
  • [8] Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies
    Boettcher, Sebastian
    Ritgen, Matthias
    Dreger, Peter
    [J]. BLOOD REVIEWS, 2011, 25 (02) : 91 - 96
  • [9] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation
    Böttcher, S
    Ritgen, M
    Pott, C
    Brüggemann, M
    Raff, T
    Stilgenbauer, S
    Döhner, H
    Dreger, P
    Kneba, M
    [J]. LEUKEMIA, 2004, 18 (10) : 1637 - 1645
  • [10] Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL
    Brander, Danielle M.
    Seymour, John F.
    Kipps, Thomas J.
    Ma, Shuo
    Anderson, Mary Ann
    Choi, Michael Y.
    Humphrey, Kathryn
    Al Masud, Abdullah
    Nandam, Ruby
    Jacobson, Amanda
    Roberts, Andrew W.
    [J]. BLOOD, 2019, 134
1234567